LEVEL 1A EVIDENCE

Hyperthermia Treatment for

Head & Neck Cancer

In total 451 clinical cases from six studies were included in the meta- analysis. Five of six trials were randomised. The overall CR with radiotherapy alone was 39.6% (92/232).

With thermoradiotherapy, the overall CR reported was 62.5% (137/219). The odds ratio was 2.92 (95% CI: 1.58-5.42, p = 0.001).

The same EHY2000 device was used. The number of patients who were disease free at 3 years was 32% more in the hyperthermia group than in the chemoradiation group alone.

Overall Complete Response %

Hyperthermia along with radiotherapy enhances the likelihood of CR in HNCs by around 25% compared to radiotherapy alone with no significant additional acute and late morbidities. This level I evidence should justify the integration of hyperthermia into the multimodality therapy of HNCs.

Level 1 Evidence: Datta NR, Rogers S, Ordóñez SG, Puric E, Bodis S.
Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis.
Int J Hyperthermia. 2016;32(1):31-40. doi: 10.3109/02656736.2015.1099746. Epub 2015 Nov 16. PMID: 26928474.

To know more download our white paper with all the 1st level evidence data and research on Hypethermia Treatment for Head & Neck Cancer

DOWNLOAD HYPERTHERMIA FOR head & neck CANCER PDF

Between May 2004 and May 2008, 40 patients with advanced head and neck cancers were treated with HT and Chemoradiotherapy (70 Gy in 7 weeks and weekly cisplatin 50 mg or paclitaxel 60 mg). Treatment toxicity was not increased and the complete response was 76.23%. Overall survival was 75.69% at 1 year and 63.08% at 2 years.

Huilgol N.G. (2010b) administered RT to 26 patients and RT with HT (weekly) to 28 patients in a trial to evaluate the effects of HT on RT on head and neck tumours.

All patients were matched according to age, sex, and stage of disease. All patients received 66-70 Gy in 6.5-7 weeks. The complete response in the RT group was 42.4% and in the RT plus HT group it was 78.6% (p<0.05). The increase in OS rates in the RT plus HT group was also significant . No dose limiting thermal burns and treatment toxicity were recorded.